期刊
ALZHEIMERS RESEARCH & THERAPY
卷 10, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13195-018-0452-1
关键词
Disclosure; Preclinical; Asymptomatic; Alzheimer's disease; Prevention
资金
- National Institute on Aging
- Eli Lilly
- National Institutes of Health [AG016573]
BackgroundThe experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer's disease (AD) into clinical practice.MethodsWe interviewed 33 persons whose not elevated brain amyloid imaging biomarker result made them ineligible for a preclinical AD trial.ResultsMost participants (n=17) reported being informed that they did not demonstrate adequately elevated amyloid to qualify, whereas some (n=14) reported being told they had no amyloid or plaques. Relief (n=17) and disappointment related to not being able to participate (n=12) were the most common reactions to results. Nearly all participants would have made healthy lifestyle changes if they had received an elevated result, would have another scan, and would participate in another AD prevention trial.ConclusionsAlthough some participants may misconstrue results, disclosure of a not elevated amyloid result in the research setting causes little behavior change; willingness to participate in AD research remains.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据